Bullish option flow detected in Crispr Therapeutics with 1,861 calls trading, 1.2x expected, and implied vol increasing over 1 point to 53.61%. Jan-25 50 calls and Sep-24 40 puts are the most active options, with total volume in those strikes near 470 contracts. The Put/Call Ratio is 0.28. Earnings are expected on November 4th.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Oruka announces closing of merger with ARCA Biopharma
- Crispr Therapeutics call volume above normal and directionally bullish
- Crispr Therapeutics price target lowered to $100 from $120 at Truist
- Mid-Cap Stocks: CRSP Offers Tremendous Growth Potential With Inherent Risks
- Crispr Therapeutics price target lowered to $60 from $66 at RBC Capital